Envestnet Asset Management Inc. Has $1.46 Million Holdings in DaVita Inc. $DVA

Envestnet Asset Management Inc. trimmed its holdings in shares of DaVita Inc. (NYSE:DVA) by 32.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,981 shares of the company’s stock after selling 5,168 shares during the quarter. Envestnet Asset Management Inc.’s holdings in DaVita were worth $1,459,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in DVA. Hantz Financial Services Inc. increased its holdings in shares of DaVita by 341.6% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,020 shares of the company’s stock valued at $136,000 after acquiring an additional 789 shares during the last quarter. Jones Financial Companies Lllp grew its holdings in DaVita by 57.1% during the third quarter. Jones Financial Companies Lllp now owns 1,508 shares of the company’s stock valued at $197,000 after purchasing an additional 548 shares during the last quarter. State of Wyoming raised its position in shares of DaVita by 6.1% in the third quarter. State of Wyoming now owns 2,928 shares of the company’s stock valued at $389,000 after purchasing an additional 169 shares during the period. Mediolanum International Funds Ltd lifted its stake in shares of DaVita by 57.3% in the third quarter. Mediolanum International Funds Ltd now owns 10,840 shares of the company’s stock worth $1,416,000 after buying an additional 3,950 shares during the last quarter. Finally, Financial Strategies Group Inc. boosted its holdings in shares of DaVita by 29.1% during the 3rd quarter. Financial Strategies Group Inc. now owns 7,046 shares of the company’s stock worth $936,000 after buying an additional 1,590 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

DVA opened at $156.28 on Monday. The company has a market capitalization of $10.44 billion, a P/E ratio of 15.77, a P/E/G ratio of 0.55 and a beta of 0.93. The firm’s fifty day moving average price is $124.18 and its two-hundred day moving average price is $125.91. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $157.91.

DaVita (NYSE:DVA) last released its quarterly earnings data on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping analysts’ consensus estimates of $3.24 by $0.16. The company had revenue of $3.62 billion during the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a net margin of 5.47% and a negative return on equity of 413.18%. The firm’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the firm earned $2.24 EPS. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, equities research analysts expect that DaVita Inc. will post 10.76 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently commented on DVA. Zacks Research upgraded shares of DaVita from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. UBS Group lifted their price objective on DaVita from $186.00 to $190.00 and gave the stock a “buy” rating in a research note on Wednesday, February 4th. Weiss Ratings reissued a “hold (c)” rating on shares of DaVita in a research report on Monday, December 29th. Truist Financial set a $158.00 target price on DaVita in a report on Thursday, February 5th. Finally, TD Cowen reiterated a “hold” rating on shares of DaVita in a report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $155.80.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.